ClinicalTrials.gg
CompletedNCT03934502Updated Jul 7, 2020

Effect of Meal Composition and Timing on Evobrutinib Bioavailability

A Phase 1 interventional study of Evobrutinib in Healthy, sponsored by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany. Completed at 1 site in Germany. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-07-07.

Sponsored by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany (part of Merck KGaA, Darmstadt, Germany) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This study will evaluate the Pharmacokinetics (PK) of the Phase II tablet formulation of Evobrutinib under fasted conditions, within 30 minutes after start of a light meal, one hour prior to start of a low-fat meal, and 2 hours after start of a low-fat meal.

02

Conditions studied

  • Healthy

Keywords

  • Evobrutinib
  • Pharmacokinetics
03

In context

Lead sponsor

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany is the lead sponsor of 56 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants are overtly healthy as medical evaluation, including medical history, physical examination, laboratory tests, and cardiac monitoring
  • Participants are stable non-smokers for at least 3 months preceding screening
  • Male or female participants agree to be consistent with local regulations on methods
  • Female participants are not pregnant or breastfeeding, and at least one of the following condition applies:
  • Not a woman of (WOCBP) or
  • If a WOCBP, use a highly effective contraceptive method (that is, with a failure rate of less than (\<) 1 percent per year, preferably with low user dependency for the following time period:
  • Before the first dose of the study intervention, if using hormonal contraception:
  • Has completed at least one 4-week cycle of an oral contraception pill and either had or has begun her menses or
  • Has used a depot contraceptive or extended-cycle oral contraceptive for least 28 days and has a documented negative pregnancy test using a highly sensitive assay and
  • A barrier method
  • During the intervention period
  • After the study intervention period (that is after the last dose of study intervention is administered) for at least 90 days, plus 30 days (a menstrual cycle) after the last dose of study intervention and agree not to donate eggs (ova, oocytes) for reproduction during this period. The Investigator evaluates the effectiveness of the contraceptive method in relationship to the first dose of study intervention
  • Females have a negative serum pregnancy test at the Screening Visit and within 24 hours before the first dose of study intervention If a urine test cannot be confirmed as negative (example: an ambiguous result), a serum pregnancy test is required
  • The Investigator reviews the medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a female with an early undetected pregnancy
  • Male participants should agree to the following during the study intervention period and for at least 3 months
  • after the last dose of study intervention:
  • Refrain from donating sperm,
  • plus either:
  • Abstain from intercourse with a female, Or
  • use a male condom:
  • When having sexual intercourse with a WOCBP, who is not currently pregnant, and advise her to use a highly effective contraceptive method with a failure rate of \<1 percent per year, since a condom may break or leak
  • Other protocol defined inclusion criteria could apply

Exclusion criteria

Exclusion Criteria:

  • History or presence of respiratory, gastrointestinal, renal, hepatic, haematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, connective tissue diseases or disorders.
  • Prior history of cholecystectomy or splenectomy, and any clinically relevant surgery within 6 months prior to screening
  • History of any
  • History of chronic or recurrent acute infection or any bacterial, viral, parasitic or fungal infections within 30 days prior to screening and at any time between screening and admission, or hospitalization due to infection within 6 months prior to screening
  • History of shingles within 12 months prior to screening
  • History of drug , ascertained or presumptive allergy/hypersensitivity to the active drug substance and/or formulation ingredients
  • History of alcoholism or drug abuse within 2 years prior to screening, or evidence of such abuse as indicated by the laboratory assays conducted during screening
  • History of residential exposure to tuberculosis, or a positive QuantiFERON® test within 4 weeks prior to screening
  • Administration of or live-attenuated virus vaccines within 3 months prior to screening
  • Any condition, including findings in the laboratory tests, medical history, or other screening assessments, that in the opinion of the Investigator constitutes an inappropriate risk or a for participation in the study or that could interfere with the study's objectives, conduct, or evaluation
  • Other protocol defined exclusion criteria could apply
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Evobrutinib: Treatment Sequence A, B, C, D

    Participant will receive single oral dose of evobrutinib after an overnight fast of at least 10 hours (Treatment A) for 3 days, followed by within 30 minutes after start of a light meal (Treatment B) for 2 days, followed by 1 hour prior to a low-fat meal (Treatment C) for 2 days, followed by 2 hours after start of low-fat meal (Treatment D) for 2 days. There will be 48 hours washout period between each treatment period.

    Drug: Evobrutinib

  • Experimental
    Evobrutinib: Treatment Sequence B, D, A, C

    Participant will receive single oral dose of evobrutinib within 30 minutes after start of a light meal (Treatment B) for 3 days, followed by 2 hours after start of a low-fat meal (Treatment D) for 2 days, followed by after an oversight fast of at least 10 hours (Treatment A) for 2 days, followed by 1 hour prior to a low-fat meal (Treatment C) for 2 days. There will be 48 hours washout period between each treatment period.

    Drug: Evobrutinib

  • Experimental
    Evobrutinib: Treatment Sequence C, A, D, B

    Participant will receive single oral dose of evobrutinib 1 hour prior to a low-fat meal (Treatment C) for 3 days, followed by after an oversight fast of at least 10 hours (Treatment A) for 2 days, followed by 2 hours after start of a low-fat meal (Treatment D) for 2 days followed by within 30 minutes after start of a light meal (Treatment B) for 2 days. There will be 48 hours washout period between each treatment period.

    Drug: Evobrutinib

  • Experimental
    Evobrutinib: Treatment Sequence D, C, B, A

    Participant will receive single oral dose of evobrutinib 2 hours after start of a low-fat meal (Treatment D) for 3 days, followed by 1 hour prior to a low-fat meal (Treatment C) for 2 days, followed by within 30 minutes after start of a light meal (Treatment B) for 2 days, followed by after an overnight fast of at least 10 hours (Treatment A) for 2 days. There will be 48 hours washout period between each treatment period.

    Drug: Evobrutinib

Interventions

  • Participants will receive single oral dose of evobrutinib either after an overnight fast of at least 10 hours (Treatment A), within 30 minutes after start of a light meal (Treatment B), 1 hour prior to a low-fat meal (Treatment C), or 2 hours after start of a low-fat meal (Treatment D).

    Also known as: M2951

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-t) of Evobrutinib

    Time frame: Pre-dose up to 24 hours post-dose

  2. Area Under the Plasma Concentration-Time Curve from Time Zero to Infinity (AUC0-inf) of Evobrutinib

    Time frame: Pre-dose up to 24 hours post-dose

  3. Maximum Plasma Concentration Observed (Cmax) of Evobrutinib

    Time frame: Pre-dose up to 24 hours post-dose

Secondary outcomes

  1. Number of Participants With Treatment -Emergent Adverse Events (TEAEs)

    Time frame: Day 1 up to Day 9

  2. Number of Participants With Clinically Significant Change From Baseline in Vital Signs, Laboratory Parameters and Electrocardiogram Findings

    Number of participants with clinically significant change from baseline in vital signs, laboratory parameters and electrocardiogram findings will be reported

    Time frame: Day 1 up to Day 9

  3. Area Under the Plasma Concentration-Time Curve From Time Zero to Time 24 Hours After Drug Administration (AUC0-24) of Evobrutinib

    Time frame: Pre-dose up to 24 hours post-dose

  4. Area Under The Concentration-Time Curve from Time Zero to Time 12 Hours (AUC0-12) of Evobrutinib

    Time frame: Pre-dose up to 12 Hours post-dose

  5. Time to Reach Maximum Concentration (Tmax) of Evobrutinib in Plasma

    Time frame: Pre-dose up to 24 hours post-dose

  6. Time Prior to the First Measurable (non-zero) Concentration of Evobrutinib

    Time frame: Pre-dose up to 24 hours post-dose

  7. Apparent Elimination Half Life (t1/2) of Evobrutinib

    Time frame: Pre-dose up to 24 hours post-dose

  8. Apparent Clearance (CL/f) of Evobrutinib

    Time frame: Pre-dose up to 24 hours post-dose

  9. Apparent Volume of Distribution During Terminal Phase (VZ/f) of Evobrutinib

    Time frame: Pre-dose up to 24 hours post-dose

07

Study locations

1 site
  • Nuvisan GmbH
    Neu-Ulm, 89231, Germany
08

References and documents

Individual participant data

Plan to share: No — Per company policy, following approval of a new product or a new indication for an approved product in both the EU and the US, Merck Healthcare KGaA, Darmstadt Germany, an affiliate of Merck KGaA, Darmstadt, Germany will share study protocols, anonymized patient level and study level data and redacted clinical study reports from clinical trials in patients with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website https://www.merckgroup.com/en/research/our-approach-to-research-and-development/healthcare/clinical-trials/commitment-responsible-data-sharing.html

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2019 to primary completion in Jun 2019, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2019
First posted
May 2, 2019
StartActual
Apr 15, 2019
Primary completionActual
Jun 12, 2019
CompletionActual
Jun 12, 2019
Last update
Jul 7, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03934502
Responsible party
Sponsor
First posted
May 2, 2019
Start date
Apr 15, 2019
Primary completion
Jun 12, 2019
Completion
Jun 12, 2019
Last update
Jul 7, 2020

Study contacts

Medical Responsible
study director · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Evobrutinib

Start the discussion